Immuneering (IMRX) Free Cash Flow (2020 - 2024)
Historic Free Cash Flow for Immuneering (IMRX) over the last 5 years, with Q4 2024 value amounting to -$14.5 million.
- Immuneering's Free Cash Flow fell 2154.47% to -$14.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$55.1 million, marking a year-over-year decrease of 1170.74%. This contributed to the annual value of -$55.1 million for FY2024, which is 1170.74% down from last year.
- As of Q4 2024, Immuneering's Free Cash Flow stood at -$14.5 million, which was down 2154.47% from -$13.5 million recorded in Q3 2024.
- In the past 5 years, Immuneering's Free Cash Flow ranged from a high of -$3.5 million in Q3 2020 and a low of -$15.5 million during Q1 2024
- Its 5-year average for Free Cash Flow is -$10.5 million, with a median of -$11.3 million in 2022.
- In the last 5 years, Immuneering's Free Cash Flow plummeted by 15907.59% in 2021 and then crashed by 108.48% in 2023.
- Over the past 5 years, Immuneering's Free Cash Flow (Quarter) stood at -$5.5 million in 2020, then crashed by 68.49% to -$9.3 million in 2021, then dropped by 27.73% to -$11.8 million in 2022, then decreased by 1.08% to -$11.9 million in 2023, then decreased by 21.54% to -$14.5 million in 2024.
- Its last three reported values are -$14.5 million in Q4 2024, -$13.5 million for Q3 2024, and -$11.6 million during Q2 2024.